atrial fibrillation
Conditions
Interventions
group of anticoagulant:Oral anticoagulant
group of nonanticoagulant:Nil
Sponsors
Affiliated Hospital of Yunnan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years; 2. Patients with atrial fibrillation; 3. High embolism risk (CHA2DS2-VASc table 1 male is greater than 2 points, female is greater than 3 points); 4. High bleeding risk (HAS-BLED table 2 is greater than 3 points); 5. The patient voluntarily joined the trial and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Take amiodarone and other antiarrhythmic drugs with cardioversion function; 2. Radiofrequency ablation has been performed; 3. The left atrial appendage has been occluded; 4. There is obvious active bleeding (digestive tract bleeding, acute cerebral hemorrhage); 5. Chronic renal insufficiency (creatinine clearance rate is less than 30mL/min.1.73 m2); 6. Combined with abnormal coagulation function or blood system disease; 7. Atrial fibrillation caused by other secondary factors; 8. Moderate or severe liver injury (Child-Pugh classification is B or C); 9. Women who are pregnant, breastfeeding, planning to become pregnant, or women of childbearing age who have not adopted reliable contraceptive methods; 10. Patients with acute coronary syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cardiovascular mortality;All cause death;Bleeding event;Thromboembolic events; | — |
Countries
China
Contacts
Public ContactJunwen Wang
Affiliated Hospital of Yunnan University
Outcome results
None listed